U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339878) titled 'Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma' on Jan. 05.
Brief Summary: The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians t...